Walleye Capital
PRLD icon

Walleye Capital’s Prelude Therapeutics PRLD Stock Holding History

Walleye Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-83,175
Closed -$172K – 5409
2024
Q3 		$172K Buy
83,175
+67,946
+446% +$315K ﹤0.01% 4103
2024
Q2 		$58K Sell
15,229
-1,151
-7% -$4.68K ﹤0.01% 4890
2024
Q1 		$77.6K Buy
+16,380
New +$63.7K ﹤0.01% 4516
2022
Q1 		– Sell
-41,954
Closed -$522K – 2529
2021
Q4 		$522K Buy
+41,954
New +$683K 0.02% 961

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Walleye Capital's PRLD Position: Q4 2024 in Review

Walleye Capital sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 83,175 shares — an estimated $172K sold.

Walleye Capital first reported a position in PRLD in Q4 2021 and held it in 4 quarters. The position peaked at $522K in Q4 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Walleye Capital reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 83,175 Prelude Therapeutics shares in Q4 2024, an estimated $172K.
  • Walleye Capital first reported a position in Prelude Therapeutics in Q4 2021 and held it in 4 quarters.
  • Walleye Capital's Prelude Therapeutics position peaked at $522K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.